MedTrace Logo

Clinical Characteristics, Etiologies, and Outcomes of Patients With Haematochezia at Al-Rajhi University Hospital.

NCT07157228 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-09-05

No results posted yet for this study

Summary

Haematochezia is the passage of bright red or maroon blood or blood clots from the rectum, usually originates from a source in lower parts of the gastrointestinal (GI) tract

* In addition, haematochezia can be seen in patients with brisk upper gastrointestinal bleeding (UGIB). The underlying etiology can vary from life threatening variceal bleeding to clinically insignificant haemorrhoidal bleeding . The most common etiology is diverticular bleeding, which accounts for 20% to 55% of cases, followed by intestinal ischemia, inflammatory bowel diseases, anorectal disorders, and neoplasia, which each accounting for around 10% of cases
* LGIB can be mild and intermittent or moderate or severe . Patients with mild bleeding can be electively evaluated as outpatients. While, those with severe bleeding should be hospitalized for management Acute or severe LGIB has an incidence of 20-30 cases/100,000 person years and accounts for 20% of GI bleeds (7-8). The overall mortality rate of LGIB is 2-4% .

Clinical data available at the time of initial patient evaluation can be used to identify patients at high risk for severe bleeding and other adverse outcomes. Several scoring systems have been developed to assess risk in acute LGIB .

To the best of our knowledge, no Egyptian study has addressed the outcome of patients with haematochezia presented at the endoscopy units or has evaluated the clinical utility of risk scores in assessment of patients admitted to hospitals with acute haematochezia. Therefore, we need to study the short-term outcomes of patients with haematochezia (and their predictors) after being managed.

Conditions

  • Haematochezia

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-10-01
Completion
2026-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07157228 on ClinicalTrials.gov